Quick Takeaways
- This page summarizes Gregory D. Davis's Form 4 filing for SANGAMO THERAPEUTICS, INC (SGMO).
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 26 Jan 2026, 16:08.
Gregory D. Davis - 22 Jan 2026 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)
- Signature
- /s/ Scott Willoughby, Attorney-in-Fact
- Issuer symbol
- SGMO
- Transactions as of
- 22 Jan 2026
- Net transactions value
- -$3,077
- Form type
- 4
- Filing time
- 26 Jan 2026, 16:08:45 UTC
- Previous filing
- 26 Nov 2025
- Next filing
- 26 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Gregory D. Davis filed Form 4 for SANGAMO THERAPEUTICS, INC (SGMO) on 26 Jan 2026."
What Changed
- Previous filing in this sequence was filed on 26 Nov 2025.
- Current net transaction value: -$3,077.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Reporting Owners (1)
| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Davis Gregory D | Head of Research & Technology | C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND | /s/ Scott Willoughby, Attorney-in-Fact | 26 Jan 2026 | 0002041855 |
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SGMO | Common Stock | Tax liability | $3,077 | -7,721 | -3.9% | $0.3985 | 191,062 | 22 Jan 2026 | Direct | F1, F2, F3, F4 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. |
| F2 | Includes: (a) 11,029 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 2,022 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
| F3 | Includes 5,000 shares acquired on May 30, 2025 under the Issuer's 2020 Employee Stock Purchase Plan. |
| F4 | The Reporting Person previously transferred 8 shares of the Issuer's common stock to his ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse. |